Campath Use in Multiple Sclerosis
The U.S. Food and Drug Administration (FDA) has licensed Campath® (alemtuzumab) for the treatment of a kind of leukemia called B-cell chronic lymphocytic leukemia (B-CLL). This medication is a monoclonal antibody and works by binding to an antigen on white blood cells, which causes the cancer cells to die.
Although this drug is primarily given for B-CLL, healthcare providers may recommend the use of Campath in multiple sclerosis treatment. This is called an "off-label" use and refers to the practice of prescribing a drug for a condition it is not approved to treat. This is a common practice and is not unlawful.
(Click Campath Uses for more information on this topic, including details on whether children and older adults can use it.)